Catalyst Event
BioNTech SE (BNTX) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
3/24/2026, 12:00:00 AM
Announced on March 24, 2026, the presentation of new positive clinical data for its late-stage lung cancer portfolio at the European Lung Cancer Congress (ELCC); this milestone is estimated to have a ≥5% price impact.
Korean Translation
2026년 3월 24일, 유럽폐암학회(ELCC)에서 후기 단계 폐암 포트폴리오에 대한 새로운 긍정적 임상 데이터를 발표함. 임상 성과 발표로 인해 5% 이상의 주가 영향이 예상됨.
Related Recent Events
Recursion Pharmaceauticals Inc (RXRX) · Earnings Release
First quarter 2026 earnings release is scheduled for May 11, 2026, with analysts forecasting an EPS of approximately -$0.25. This event is critical for monitoring cash burn, justifying a medium importance estimate (expected 5-10% impact), forecasted
5/11/2026, 12:00:00 AM
Tempus AI Inc (TEM) · Earnings Release
As quarterly earnings are key volatility events for growth-stage AI companies, Tempus AI's Q1 2026 earnings release on May 5, 2026, is scheduled
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release is scheduled; medium importance is estimated based on expected >=5% price impact.
4/30/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Earnings Release
Alphabet's Q1 2026 earnings release on April 23, 2026, with low importance estimated as no market reaction has occurred yet, expected.
4/23/2026, 12:00:00 AM
Intuitive Surgical Inc (ISRG) · Earnings Release
Q1 2026 earnings release and conference call for 2026-04-21 scheduled. Low importance is estimated due to the routine nature of the announcement scheduled.
4/21/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
FDA decision on oral weight-loss drug orforglipron is expected; high importance is estimated due to potential for >=10% price impact.
4/10/2026, 12:00:00 AM